Raykov Rosty's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Dec 30, 2022
- Accession no.
- 0001415889-22-013104
- Filed
- Dec 30, 2022
- Trade date
- Dec 28-30, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $276.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Raykov RostyCIK 0001468316 | Director, Officer (CHIEF EXECUTIVE OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2022 | Common shares | SSaleDisposed | −13,740 | $9.59 | −$131,766.6 | 232,838 | Direct | |
| Dec 29, 2022 | Common shares | SSaleDisposed | −5,000 | $9.65 | −$48,250 | 227,838 | Direct | |
| Dec 30, 2022 | Common shares | SSaleDisposed | −1,600 | $9.66 | −$15,456 | 226,238 | Direct | |
| Dec 30, 2022 | Common shares | SSaleDisposed | −8,400 | $9.61 | −$80,724 | 217,838 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.